CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Niladri ChattopadhyayTobias KanacherManuela CasjensSebastian FrechenSandra LiggesTorsten ZimmermannAntje RottmannBart PloegerJoachim HöchelMarcus-Hillert Schultze-MosgauPublished in: British journal of clinical pharmacology (2018)
The exposure to vilaprisan was reduced by 96%. Such a reduction is likely to render the drug therapeutically ineffective. Therefore, it is recommended that the use of strong CYP3A4 inducers is avoided when taking vilaprisan.